Writer, thinker, entrepreneur, philanthropist Abdul Raheem Teekay passes away at 65

coastaldigest.com web desk
February 15, 2019

Mangaluru, Feb 15: Abdul Raheem Teekay, a well-known writer, thinker, activist and advocate of communal amity in coastal Karnataka passed away after a brief illness today at his residence in the city.

The 65-year-old philanthropist is survived by his wife, two children, four brothers and a large number of relatives, friends and fans.

A tweet-heart and social media enthusiast who always tried to bridge gaps between people, Raheem Teekay was a successful businessman and managing director of Teekays Corporate Concepts Pvt Ltd.

His writings in Kannada and Beary languages have earned him many fans. He translated Paulo Coelho’s international bestseller The Alchemist into Kannada. It was released as Rasavadi in 2015. His anthology of Beary poems Mallige Balli was released in 2014. His several English articles were published on coastaldigest.com too.

He was one of the pioneers of Beary literary and cultural movement. He was the founder president of Kendra Beary Sahitya Parishat.

Born in Jokatte as the second son of Bava Abdul Khader and Salma couple, Raheem Teekay was brought up in Bajpe. For past several decades he was residing in Mangaluru city. By establishing Salma Bava Foundation, he has helped hundreds of children from poor families in coastal Karnataka.

Comments

Jalal UK
 - 
Friday, 15 Feb 2019

A rare human being. In spite of all his social service, philanthropic activities and social media engagements, he spent most of his time with his family members. His demise is a big loss to all who know him.

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
coastaldigest.com web desk
July 1,2020

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
July 2,2020

Bengaluru, Jul 2: Karnataka government has issued a show-cause notice to 18 private hospitals for refusing to admit a 52-year-old patient with influenza-like illness (ILI) symptoms, who later died.

According to the notice dated on June 30, a 52-years patient named Bhawarlal Sujani died after he was denied admission by 18 private hospitals.

The patient was taken to these hospitals on Saturday and Sunday for admission on observing some ILI like symptoms. But none of these hospitals admitted in on the pretext of unavailability of bed/ventilators, read the notice.

This is a clear violation of providing medical assistance and admission necessitated under the agreed provision of KPME Registration. They should strictly adhere to the provisions under Sections 11 & 11 A of KPME Act 2017. Private Medical Establishments cannot deny/ refuse/ avoid treatment to patients with Covid-19 and Covid-19 like symptoms, the state Health Department said.

By denying the admission to the deceased patient, your hospitals have violated the provisions of the above-said act. You are liable for legal action in this regard, as per the notice.

The state Health department asked the hospitals to reply as to why action should not be initiated under the relevant Acts. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 2,2020

Bengaluru, Apr 2: A health worker, who was part of a team fighting against the Coronavirus disease in the city, was allegedly attacked by a mob and duped of her belongings at the Sadiq Layout in the Shivajinagar area on Thursday.

According to police sources, the health worker came under attack by a mob of youths when she was collecting data from those who were sick in the locality.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.